Methods and products for transfecting cells

Patent metadata

Field	Value
Publication number	US-12391961-B2
Application number	US-202318332621-A
Country	US
Kind code	B2
Filing date	Jun 9, 2023
Priority date	Dec 5, 2011
Publication date	Aug 19, 2025
Grant date	Aug 19, 2025

Abstract

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

First claim

What is claimed is:

1. A method for generating gene-edited cells, the method comprising:
(a) providing a plurality of cells comprising a target DNA sequence, wherein the plurality of cells is derived from a human subject;
(b) culturing the plurality of cells under conditions that allow the plurality of cells to proliferate; and
(c) contacting the plurality of cells in vitro or ex vivo with a plurality of synthetic RNA molecules,
wherein the plurality of synthetic RNA molecules comprises a nucleotide sequence that encodes a transcription activator-like effector nuclease,
wherein the plurality of synthetic RNA molecules is added to a medium surrounding the plurality of cells, and
wherein the contacting results in the plurality of cells internalizing the plurality of synthetic RNA molecules and expressing the transcription activator-like effector nuclease to result in a single-strand break or a double-strand break in the target DNA sequence, thereby generating the gene-edited cells.

2. The method of claim 1 , wherein the plurality of cells comprises hematopoietic cells.

3. The method of claim 2 , wherein the hematopoietic cells comprise hematopoietic stem cells.

4. The method of claim 2 , wherein the hematopoietic cells comprise white blood cells.

5. The method of claim 1 , wherein the plurality of cells is obtained from a biopsy sample from the human subject.

6. The method of claim 5 , wherein the biopsy sample is a dermal punch biopsy.

7. The method of claim 1 , wherein the gene-edited cells comprise a gene that is edited to reduce or eliminate its function.

8. The method of claim 1 , wherein the plurality of cells is transfected with a nucleic acid molecule that encodes at least one of: p53, TERT, a cytokine, a secreted protein, a membrane-bound protein, an enzyme, a gene-editing protein, a chromatin-modifying protein, a DNA-binding protein, a transcription factor, a histone deacetylase, a pathogen-associated molecular pattern, and a tumor-associated antigen.

9. The method of claim 1 , wherein the plurality of cells is transfected with a nucleic acid molecule that encodes a membrane-bound protein.

10. The method of claim 1 , wherein the medium comprises at least one of: poly-L-lysine, poly-L-ornithine, RGD peptide, fibronectin, vitronectin, collagen, and laminin.

11. The method of claim 1 , wherein the plurality of synthetic RNA molecules is complexed with a transfection reagent.

12. The method of claim 11 , wherein the transfection reagent is lipid-based, polymer-based, or peptide-based.

13. The method of claim 11 , wherein the transfection reagent comprises a cationic lipid, a liposome, or a micelle.

14. The method of claim 1 , wherein the medium is substantially free of immunosuppressants.

15. The method of claim 1 , wherein the medium is free of irradiated human neonatal fibroblast feeders.

16. The method of claim 1 , wherein the plurality of synthetic RNA molecules comprises at least one non-canonical nucleotide selected from the group consisting of: a 5-methyluridine residue, a pseudouridine residue, a 5-methylpseudouridine residue, a 5-hydroxyuridine residue, a 5-hydroxypseudouridine residue, and a 5-methylcytidine residue.

17. The method of claim 1 , wherein the plurality of synthetic RNA molecules further comprises one or more of a 5′-cap, a 5′-cap 1 structure, and a 3′-poly(A) tail.

18. The method of claim 1 , wherein the method further comprises introducing into the gene-edited cells a DNA repair template.

19. The method of claim 18 , wherein the DNA repair template comprises one or more regions of homology to the DNA of the gene-edited cells upstream or downstream of the single-strand break or the double-strand break.

20. The method of claim 18 , wherein the DNA repair template comprises one or more regions of homology to the DNA of the gene-edited cells upstream and downstream of the single-strand break or the double-strand break.

Assignees

• Factor Bioscience Inc

Inventors

• Angel Matthew
• Rohde Christopher

Classifications

• A61K2035/124

  the cells being hematopoietic, bone marrow derived or blood cells · CPC title

• A61K35/28

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title

• C12N9/22

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

• C12N2506/09

  from epidermal cells, from skin cells, from oral mucosa cells · CPC title

• C12N2501/91

  Heparin · CPC title